

Thermo Fisher Scientific Announces Plans to Build State-of-the-Art Pharma Services Facility in Rheinfelden (Baden) Germany

New site will support complex clinical research and bring more than 200 new jobs to community

RHEINFELDEN, Germany, March 16, 2018 /[PRNewswire](#)/ -- Thermo Fisher Scientific announced today it is expanding its footprint in the European Union and investing \$35 million in a state-of-the-art pharma services supply chain facility in Rheinfelden (Baden) Germany. Company representatives joined Mayor Eberhardt at the Rheinfelden council meeting to unveil the details of the project earlier today.

The new facility will leverage the latest technology and modern infrastructure to significantly increase European capacity for cold and ambient clinical trial materials in support of complex clinical research and so meet the growing needs of customers. The facility will be scalable for mixed-use space and provide a strategic logistical location for shipping either by road or air.

Mayor Eberhardt acknowledged local support for the project stating, "We are looking forward to partnering with Thermo Fisher Scientific to bring this new facility to life in our community which will create significant opportunity for jobs in the expanding life sciences segment. We are confident their investment will benefit our local economy and create greater opportunities for our citizens."

The company expects to start construction in Q4' 2018 for the 8,000 square meter facility at the 26,000 square meter site with an anticipated completion within 12 to 18 months. Once complete, this new facility will provide up to 200 new jobs locally. The investment includes the option for additional expansion with the potential for doubling the footprint.

"This is an exciting time for our business, and it reinforces our commitment to best serve our clients globally. By creating a best-in-class supply chain facility in the EU, we open new opportunities to support client and patient need," said Astrid Frank, Vice President and General Manager, Europe, Fisher Clinical Services.

The company's decision to expand is in response to a growing demand for global clinical supply services, worldwide. The new facility will also serve to address GDP guidelines, Clinical Trial Regulations Annex 6 and the new Falsified Medicines Directive 2019. This GMP/GDP facility builds on the company's existing footprint of 20 purpose-built cGMP facilities globally.

Thermo Fisher's Pharma Services develops unique solutions and business models to help customers manage the clinical development process and provides flexible manufacturing options to address client needs in an evolving marketplace.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of \$20 billion and more than 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Media Contact Information:


Name: Mari Mansfield

Title: Senior Director, External Communication

Phone: (919) 632-4712

Email: mari.mansfield@patheon.com

SOURCE Thermo Fisher Scientific

Additional assets available online:  [Photos \(1\)](#)

<https://thermofisher.mediaroom.com/2018-03-16-Thermo-Fisher-Scientific-Announces-Plans-to-Build-State-of-the-Art-Pharma-Services-Facility-in-Rheinfelden-Baden-Germany>